71 indexable Clinical Genomics companies headquartered in England, United Kingdom, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $710.5M across 36 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Tagomics
Developer of genomic-based cancer diagnostic platform |
$8.4M | — | Series A | Grant (prize money) Jun 2025 | 8 | 2020 | ↑ Active |
| 2 |
Genedrive
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis |
$9.3M | — | Public | Post IPO Apr 2025 | 43 | 2000 | ↑ Active |
| 3 |
ReadyGo
Provider of diagnostic test and sample collection tools for research labs |
$3.2M | $21.5M as of 2022 |
Seed | Seed Mar 2025 | 8 | 2020 | ↑ Active |
| 4 |
Sano
Provider of clinical trial recruitment and genetic testing research services |
$26.5M | — | Series A | Series A Jan 2024 | 10 | 2016 | — |
| 5 |
QuantuMDx Group
Manufacturer of molecular diagnostic platforms and assays for infectious diseases |
$57.3M | — | Series D | Series D Aug 2022 | 98 | 2008 | — |
| 6 |
Inivata
Developer of liquid biopsy platform for detecting cancer |
$188.8M | $205M as of 2020 |
Acquired | Series C Feb 2021 | 81 | 2014 | — |
| 7 |
Microbiotica
Developer of live bacterial therapeutics and biomarkers for multiple diseases |
$82.8M | $37.3M as of 2018 |
Series B | Series B Mar 2022 | 42 | 2016 | — |
| 8 |
Oxford Biodynamics
Developer of personalized diagnostics by identifying biomarkers through epigenetics |
$11M | — | Public | Grant (prize money) May 2023 | 39 | 2007 | — |
| 9 |
GEN inCode
Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring |
$4.5M | — | Public | Post IPO Dec 2023 | 26 | 2018 | — |
| 10 |
ReViral
Developer of antiviral compounds for RSV |
$121M | — | Acqui-Hired | Series C Aug 2020 | 28 | 2011 | — |
| 11 |
Circulogene
Developed cell-free DNA liquid biopsy tests for cancer |
$4.3M | — | Series A | Conventional Debt Mar 2023 | 51 | 2015 | — |
| 12 |
Oxford Cancer Biomarkers
Developer of biomarker diagnostics for cancer therapies |
$4.6M | $22M as of 2023 |
Series B | Series B Apr 2023 | 12 | 2011 | — |
| 13 |
Treos Bio
Developer of cancer vaccines and companion diagnostics |
$22M | $45.2M as of 2020 |
Series B | Series B Mar 2021 | 12 | 2013 | — |
| 14 |
Blue Earth Diagnostics
Developer of radioactive molecular imaging agents for cancer |
$49.4M | — | Acquired | Series B Jul 2015 | 38 | 2014 | — |
| 15 |
Molmart
Provider of genetic testing services |
$381.2K | — | Seed | Seed Apr 2024 | 4 | 2018 | — |
| 16 |
Valirx
Developer of novel technologies and products in oncology therapeutics and diagnostics |
$13.6M | — | Public | Post IPO Jun 2019 | 7 | 2000 | — |
| 17 |
Cytox
Developer for prognostic tests for assessing the risk of dementia |
$12.1M | — | Series B | Series B Aug 2019 | 12 | 2007 | — |
| 18 |
Luas Diagnostics
Developer of sensors and connected app for diabetes management |
$949.1K | $3M as of 2023 |
Seed | Seed Apr 2023 | 3 | 2020 | — |
| 19 |
Suisse Life Science
Direct to consumer genetic profiling and associated services |
$20M | — | Acquired | Series B Jun 2018 | — | 2014 | — |
| 20 |
Base Genomics
Provider of in-vitro DNA methylation based detection test for early stage of cancer |
$11M | — | Acqui-Hired | Seed Jun 2020 | 19 | 2019 | — |
| 21 |
Yourgene Health
Provider of non-invasive prenatal genetic tests and genomic services |
$15.3M | — | Public | Post IPO Apr 2019 | 253 | 2000 | — |
| 22 |
14M Genomics
Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics |
$19.7M | — | Deadpooled | Series A Dec 2014 | 20 | 2014 | — |
| 23 |
Fluoretiq
Developer of a diagnostic platform for bacterial identification |
$2.5M | — | Seed | Seed Feb 2022 | 9 | 2017 | — |
| 24 |
ArquerDx
Develops urine-based immunoassay tests for genitourinary cancers. |
$5.4M | — | Series A | Series A Apr 2019 | 9 | 2007 | — |
| 25 |
Lumora
Developer of molecular diagnostics for infectious diseases |
$7.4M | — | Acqui-Hired | Series B Mar 2013 | 19 | 2003 | — |
| 26 |
Cambridge Cancer Genomics
Developer of AI-based precision medicine tools for oncologists |
$4.6M | — | Acqui-Hired | Series A Dec 2018 | 16 | 2015 | — |
| 27 |
Micropathology
Provider of services for the rapid diagnosis and management of infectious and genetic disease, |
$1.2M | — | Funding Raised | Grant (prize money) Jan 2020 | — | 1995 | — |
| 28 |
Omixy
Complete -omics profile |
$1.5M | — | Deadpooled | Seed Nov 2015 | 12 | 2015 | — |
| 29 |
Mursla
Provider of diagnostic device for cancer detection |
$547.2K | — | Seed | Seed Sep 2020 | 9 | 2017 | — |
| 30 |
Qbiotix
Developer of nucleic acid-based assays for microbial disease detection |
$309.3K | $3M as of 2020 |
Seed | Seed Mar 2020 | — | 2019 | — |
| 31 |
Odin Vision
Provider of AI-based colon cancer detection platform |
$367.7K | — | Acquired | Seed May 2019 | 12 | 2019 | — |
| 32 |
Elucigene
Provider of in vitro diagnostics for cystic fibrosis and other genetic diseases |
$263K | — | Acquired | Grant (prize money) Oct 2014 | 180 | 2013 | — |
| 33 |
MetaGuideX
Provider of in-vitro diagnostics to predict cancer metastasis |
$66.7K | — | Seed | Seed Nov 2020 | 3 | 2020 | — |
| 34 |
Cambridge Protein Arrays
Developer of DNA microarray to protein microarray(DAPA) platform |
$119.7K | — | Funding Raised | Grant (prize money) Jan 2017 | 2 | 2010 | — |
| 35 |
BioMe Oxford
Provider of a gut-sampling device for the diagnostics of gastrointestinal disorders |
$32.7K | — | Seed | Seed Aug 2016 | 4 | 2014 | — |
| 36 |
Geneix
Bringing precision prescribing into routine care |
$28.4K | — | Seed | Seed Jan 2014 | 1 | 2012 | — |
| 37 |
Vivan Therapeutics
Developer of personalized cancer‑therapeutics platform |
— | — | Funding Raised | Grant (prize money) 2022 | 15 | 2018 | — |
| 38 |
MultiplAI Health
Developer of an AI-enabled in vitro diagnostic system for the detection of cancer |
— | — | Seed | Seed Feb 2021 | 4 | 2019 | — |
| 39 |
CanCertain
Developer of personalized tests to detect cancer for precision medicines |
— | — | Seed | Seed Aug 2018 | 9 | 2017 | — |
| 40 |
4N GeneHealth
Provider of DNA-based genetic testing service to predict future disease risk |
— | — | Deadpooled | — | — | 2016 | — |
| 41 |
Advanced Cancer Diagnostics
Provider of cancer diagnostics tests |
— | — | Deadpooled | — | — | 2016 | — |
| 42 |
Aequa Science
Provides AI-based solutions to predict Alzheimer's disease |
— | — | Deadpooled | — | — | 2016 | — |
| 43 |
AlphaBiomics
Developer of microbiome-based precision therapies |
— | — | Funding Raised | — | 3 | 2018 | — |
| 44 |
Anglia DNA
Provider of drug, alcohol and DNA testing services |
— | — | Unfunded | — | — | 2004 | — |
| 45 |
Applied Biotech
Provider of liquid biopsy based detection tool for cancer diagnostics |
— | — | Funding Raised | — | 3 | 2019 | — |
| 46 |
Apterna
Provider of precision RNA aptamers for therapeutics and drug delivery |
— | — | Unfunded | — | — | 2011 | — |
| 47 |
Cambridge Precision Medicine
Developer of precision medicine by using genome sequencing |
— | — | Funding Raised | — | 2 | 2017 | — |
| 48 |
Cell Analysis
Provider of SNP test kits for diagnosis of hematological and oncological diseases |
— | — | Deadpooled | — | — | 1996 | — |
| 49 |
Cellmark Forensic Services
Provider of forensic and DNA testing services |
— | — | Acquired | — | 338 | 1987 | — |
| 50 |
Complement Genomics
Genome sequencing company |
— | — | Unfunded | — | 13 | 2000 | — |
Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer.
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.
Provider of diagnostic test and sample collection tools for research labs. The company offers a sample collection product called "Snap" and a diagnostic testing product called "Snapshot". Also, offers a rapid test platform for small laboratories, pharmacies, and off-grid diagnostic requirements.
Provider of clinical trial recruitment and genetic testing research services. The platform combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.
Manufacturer of molecular diagnostic platforms and assays for infectious diseases. The company's product portfolio centers on a rapid, portable PCR platform and a growing suite of multiplex molecular assays designed for point‑of‑care and near‑patient testing.
Developer of liquid biopsy platform for detecting cancer. The company's technology allows improving sensitivity and coverage of larger gene panels compared to traditional methods. Inivata’s proprietary platform TAm-Seq provides the ability to conduct next-generation sequence analysis of sizable genomic regions including entire genes or exons. Its gene panel includes a profile of 34 different cancer-related genes.
Developer of live bacterial therapeutics and biomarkers for multiple diseases. The company identifies gut bacteria linked to phenotype with unprecedented precision to discover and develop live bacterial therapeutics and biomarkers for Inflammatory bowel disease, Immuno-oncology, and Gut Epithelial Barrier Repair.
Developer of personalized diagnostics by identifying biomarkers through epigenetics. Its proprietary platform EpiSwitch provides the early detection of aberrant gene expression in very low copy numbers and in a small sample of abnormal cells, at the early stage of the disease. The test is non-invasive used for Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Breast Cancer, Diabetes Type I (T1DM), and other
GEN inCode is a developer of precision medicines by combining genetic and clinical data for cardiac disease monitoring. It provides solutions for the prevention and treatment of cardiovascular disease risk. The models are based on algorithms and machine learning which allows doctors to accurately measure and assess a patient's clinical and genetic risk.
Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.
Circulogene Theranostics delivers tumor monitoring in droplets of blood through patented liquid biopsy process. Launched its cell-free DNA (cfDNA) liquid biopsy tests for 10 tumor types including breast, lung and colon cancer. The tools, which screen for circulating cfDNA from a single drop of blood, allow doctors to plan and monitor treatment after a patient gets a cancer diagnosis.
Developer of biomarker diagnostics for cancer therapies. Its proprietary platform CancerNav is a genome-wide functional screen for gene-targeted drugs for cancer. Its other platform ToxNav is for predicting drug toxicity effects of lead compounds. Oxford Cancer Biomarkers offers a panel of diagnostic, prognostic tests, and pharmacogenomic tests for colorectal cancer developed on its platforms.
Europa
British Business Bank
Gov
Calculus Capital
Cambridge Innovation Capital
Catapult Ventures
Esperante
Oxford University Innovation
University of Cambridge
BlackOx Ventures
Cambridge Capital Group
Deepbridge Capital
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-23.
.png1506415391710){kind=logo}
_1537501792425.png){kind=logo}
